Sun Pharma gains on entering into licensing agreement for Triferic in India

15 Jan 2020 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 446.60, up by 0.80 points or 0.18% from its previous closing of Rs. 445.80 on the BSE.

The scrip opened at Rs. 447.05 and has touched a high and low of Rs. 447.95 and Rs. 445.55 respectively. So far 4670 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 484.10 on 01-Apr-2019 and a 52 week low of Rs. 350.40 on 13-May-2019.

Last one week high and low of the scrip stood at Rs. 453.55 and Rs. 439.00 respectively. The current market cap of the company is Rs. 106962.35 crore.

The promoters holding in the company stood at 54.55%, while Institutions and Non-Institutions held 33.23% and 12.23% respectively.

Sun Pharmaceutical Industries has entered into exclusive licensing and supply agreements with Rockwell Medical Inc. (Rockwell), to commercialize Rockwell's Triferic, a proprietary iron replacement and haemoglobin maintenance drug, for treating anaemia in hemodialysis patients in India. Triferic is approved in USA.

As per the terms of the agreement, Sun Pharma will be the exclusive development and commercialization partner for Triferic during the term of the agreement, subject to its approval in India. In consideration for the license, Rockwell will be eligible for upfront and milestone payments as well as royalty on net sales. The financial terms of the agreement are confidential.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. 

Sun Pharma Inds. Share Price

1786.05 -40.05 (-2.19%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.